Tacedinaline

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Tacedinaline ( , ; developmental code name CI-994), also known as N-acetyldinaline, is a histone deacetylase (HDAC) inhibitor and possible cognitive enhancer which is under development for the treatment of Alzheimer's disease. It was also under development as an antineoplastic agent for the treatment of various cancers, but development for these uses was discontinued. The drug is taken orally.

Tacedinaline ( , ; developmental code name CI-994), also known as N-acetyldinaline, is a histone deacetylase (HDAC) inhibitor and possible cognitive enhancer which is under development for the treatment of Alzheimer's disease. It was also under development as an antineoplastic agent for the treatment of various cancers, but development for these uses was discontinued. The drug is taken orally.

Side effects

Unlike many other less-selective HDAC inhibitors, which have often produced unwanted side effects, tacedinaline is said to be well-tolerated. However, adverse effects such as thrombocytopenia among others have nonetheless been observed in cancer treatment trials.

Pharmacology

Tacedinaline is a potent inhibitor of the class I HDAC1, HDAC2, and HDAC3, with values of 41–636 nM, 147–696 nM, and 46–472 nM, respectively. The drug showed no inhibition of other HDACs, including HDAC4 through HDAC11, at a concentration of 10,000 to 33,000 nM. It is more selective for class I HDACs compared to many other HDAC inhibitors. In addition to its HDAC inhibition, tacedinaline also activates Wnt/β–catenin signaling and hence is said to have a dual mechanism of action. It enhances synaptogenesis, increases central brain-derived neurotrophic factor (BDNF) expression, and decreases tau phosphorylation in preclinical research. Tacedinaline enhances cognition and memory in rodents. It crosses the blood–brain barrier. The drug's time to peak levels is approximately 1 to 2 hours and elimination half-life is 9.6 to 14 hours in humans.

Chemistry

The chemical synthesis of tacedinaline has been described. Glucuronide prodrugs of tacedinaline for targeted tumor chemotherapy have been described.

History and development

Tacedinaline was first described in the scientific literature by 1993. It was developed by Goedecke and Pfizer. As of September 2024, the drug is in the preclinical research stage of development for Alzheimer's disease. It was also under development for the treatment of breast cancer, colorectal cancer, lung cancer, and pancreatic cancer, and reached phase 2 and 3 trials for these uses in the 2000s, but development was discontinued by 2008. Subsequently, tacedinaline was repurposed for the treatment of Alzheimer's disease in the 2020s.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1369189922 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

3 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.